Choroidal Neovascularization - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 21, 2018--The “Choroidal Neovascularization - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Choroidal Neovascularization - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Report Coverage Choroidal Neovascularization - Overview Choroidal Neovascularization - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Choroidal Neovascularization - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Choroidal Neovascularization - Companies Involved in Therapeutics Development 3SBio Inc F. Hoffmann-La Roche Ltd Formycon AG Iconic Therapeutics Inc Isarna Therapeutics GmbH Lupin Ltd Mabion SA NovelMed Therapeutics Inc Noxxon Pharma AG Promedior Inc For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zzqpxk/choroidal?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005548/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/21/2018 03:09 PM/DISC: 09/21/2018 03:09 PM